We are looking forward to discussing SetPoint’s recent developments at the LifeSci Partners Private Company Summer Symposium. CEO Murthy Simhambhatla will present virtually July 22nd from 3:30 – 3:55 pm ET. #TheSetPointAdvantage #LifeSci #bioelectronicmedicine

We are excited to present our pilot rheumatoid arthritis study results at the upcoming annual @ACRheum Meeting in Atlanta this weekend! #ACR19 #TheSetPointAdvantage

SetPoint Medical celebrated the end of a productive summer with a company picnic last week to recognize our stellar employees and their families. To us, diversity and talent are vital for our mission to pioneer bioelectronic medicine. #WorkHardPlayHard #TheSetPointAdvantage

Our Director of Research, Yaakov Levine PhD will be at CCR-E to discuss the ongoing RESET-RA study. Please stop by poster in Coral B Ballroom on 8/12 to say hello and learn more about the study using vagus nerve stimulation to treat #RA. #TheSetPointAdvantage #CCREast #CCR21

Thank you, @NANS_ION, for the opportunity to present SetPoint's bioelectronic medicine platform for patients with #RA! We enjoyed the discussions to bolster advancement in #neuromodulation at the #NANSMidYear meeting. #NANS2021 #TheSetPointAdvantage

Our Chief Medical Officer David Chernoff will be at CCR-W to discuss the ongoing RESET-RA study. Please stop by poster in the Carousel room on 9/18 to say hello and learn more about the study using vagus nerve stimulation to treat #RA. #TheSetPointAdvantage #CCRWest #CCR21

#RA affects nearly 1.5 million Americans. Today, we take a moment to bring attention to this chronic disease, and raise awareness for this underserved population. #TheSetPointAdvantage #RAday

SetPoint Medical is continuously inspired by @vagusnervegirl's story as we advance our therapy so more patients like Kelly can experience the potential benefits of #BioelectronicMedicine. Read more from the @TIME article here: https://t.co/GtTZ6wEEvq #TheSetPointAdvantage

We were honored to have our national surgical PI @RMarkRichardson present RESET-RA results during the Plenary Session at #AANS25. Data presented highlight SetPoint System’s potential as a first-of-its-kind neuroimmune modulation treatment for RA. #TheSetPointAdvantage

As we continue to study our device in the #ResetRA study, we are hopeful that a better day, with more treatment options, is around the corner for many more people with chronic autoimmune conditions. #TheSetPointAdvantage #RheumatoidArthritis

We are hiring for various clinical roles. Come join the team that is revolutionizing patient care with #bioelectronicmedicine. Learn more about current opportunities: https://t.co/DeMe5pxHRr #TheSetPointAdvantage

Learn more about the potential of vagus nerve stimulation as an alternate treatment option for RA in this recent @CreakyJoints article: https://t.co/E4G1UI0ddm #TheSetPointAdvantage

Our research team, collaborating with scientists at @karolinskainst, published new data demonstrating that vagus nerve stimulation/#VNS decreases intestinal inflammation in preclinical models of inflammatory bowel disease. Read more: https://t.co/PaGlkxbG3m #TheSetpointAdvantage

Read more about our groundbreaking research for autoimmune diseases like rheumatoid arthritis in this recent article in @IEEESpectrum. #TheSetPointAdvantage #Immunology #Rheumatology #Autoimmune

New research published by @karolinskainst further validates the potential for #VagusNerve stimulation to actively resolve the damage caused by inflammatory diseases. Take a look! https://t.co/dDhatgroWu #TheSetPointAdvantage #BioelectronicMedicine #Rheumatology #Immunology #MedEd

We're happy to share that, following the recent Breakthrough Device Designation, Setpoint's neuroimmune modulation platform for the treatment of MS has now been accepted into the FDA's TAP Pilot! #TheSetPointAdvantage Learn more in our press release:

#FinancingUpdate – SetPoint Medical has secured a $35M term loan from Runway Growth Capital to support the ongoing RESET-RA clinical study as it advances #BioelectronicMedicine for #RA. Learn more here: https://t.co/TClP7zz6zV #TheSetPointAdvantage

Setpoint receives IDE for neuromodulation therapy for MS https://t.co/ARSfXl8svk #medtech @SetPointMed #TheSetPointAdvantage #MultipleSclerosis #RRMS #Autoimmune

🎉 Big news incoming: SetPoint’s novel neuroimmune modulation platform received Breakthrough Device Designation from the FDA for multiple sclerosis (MS) treatment! Learn more here: #MSAwarenessWeek #TheSetPointAdvantage https://t.co/ZuihZDbcQq

Nice story by @NPR about how neuroimmune modulation is unlocking new possibilities for treating autoimmune diseases like #RA. https://t.co/3vcbgrJ05P #TheSetPointAdvantage The SetPoint System is limited by U.S. law to investigational use only.